Vinai Gondi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinai Gondi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Minesh P. Mehta
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
5 shared publications - Wolfgang A. Tomé
Montefiore Medical Center, Department of Radiation Oncology, Bronx, NY, USA; Albert Einstein College of Medicine, Institute for Onco-Physics, Bronx, NY, USA
5 shared publications Casey T. Chollet
2 shared publicationsDeepak Khuntia
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
2 shared publicationsJennifer Keam
2 shared publications- John S. Kuo
Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
2 shared publications
Latest Publications
- Open Access
- 1 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-5
Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice
Every year 170,000 patients are diagnosed with brain metastases (BMs) in the United States. Traditionally, adjuvant whole brain radiotherapy (AWBRT) has been offered following local therapy with neurosurgery (NSx) and/or stereotactic radiosurgery (SRS) to BMs. The aim is to increase intracranial control, thereby decreasing symptoms from intracranial progression and a neurological death. There is a rapidly evolving change in the radiation treatment of BMs happening around the world. AWBRT is now being passed over in favour of repeat scanning at regular intervals and more local therapies as more BMs appear radiologically, BMs that may never become symptomatic. This change has happened after the American Society for Radiation Oncology (ASTRO) in Item 5 of its “Choosing Wisely 2014” list recommended: “Don't routinely add adjuvant whole brain radiation therapy to SRS for limited brain metastases”. The guidelines are supposed to be based on the highest evidence to hand at the time. This article debates that the randomised controlled trials (RCTs) published prior to this recommendation consistently showed AWBRT significantly increases intracranial control, and avoids a neurological death, what it is meant to do. It also points out that, despite the enormity of the problem, only 774 patients in total had been randomised over more than three decades. These trials were heterogeneous in many respects. This data can, at best, be regarded as preliminary. In particular, there are no single histology AWBRT trials yet completed. A phase two trial investigating hippocampal avoiding AWBRT (HAWBRT) showed significantly less NCF decline compared to historical controls. We now need more randomised data to confirm the benefit of adjuvant HAWBRT. However, the ASTRO Guideline has particularly impacted accrual to trials investigating this, especially the international ANZMTG 01.07 WBRTMel trial. This is an RCT investigating AWBRT following local treatment in patients with one to three BMs from melanoma. WBRTMel has accrued 196 of a required 220 to date but accrual has slowed. HAWBRT may now never be tested in a randomised setting. Encouraging more data in AWBRT is the wiser choice.
- 1 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-5
Open AccessDebate: adjuvant whole brain radiotherapy or not? More data is the wiser choice
Every year 170,000 patients are diagnosed with brain metastases (BMs) in the United States. Traditionally, adjuvant whole brain radiotherapy (AWBRT) has been offered following local therapy with neurosurgery (NSx) and/or stereotactic radiosurgery (SRS) to BMs. The aim is to increase intracranial control, thereby decreasing symptoms from intracranial progression and a neurological death. There is a rapidly evolving change in the radiation treatment of BMs happening around the world. AWBRT is now being passed over in favour of repeat scanning at regular intervals and more local therapies as more BMs appear radiologically, BMs that may never become symptomatic. This change has happened after the American Society for Radiation Oncology (ASTRO) in Item 5 of its “Choosing Wisely 2014” list recommended: “Don't routinely add adjuvant whole brain radiation therapy to SRS for limited brain metastases”. The guidelines are supposed to be based on the highest evidence to hand at the time. This article debates that the randomised controlled trials (RCTs) published prior to this recommendation consistently showed AWBRT significantly increases intracranial control, and avoids a neurological death, what it is meant to do. It also points out that, despite the enormity of the problem, only 774 patients in total had been randomised over more than three decades. These trials were heterogeneous in many respects. This data can, at best, be regarded as preliminary. In particular, there are no single histology AWBRT trials yet completed. A phase two trial investigating hippocampal avoiding AWBRT (HAWBRT) showed significantly less NCF decline compared to historical controls. We now need more randomised data to confirm the benefit of adjuvant HAWBRT. However, the ASTRO Guideline has particularly impacted accrual to trials investigating this, especially the international ANZMTG 01.07 WBRTMel trial. This is an RCT investigating AWBRT following local treatment in patients with one to three BMs from melanoma. WBRTMel has accrued 196 of a required 220 to date but accrual has slowed. HAWBRT may now never be tested in a randomised setting. Encouraging more data in AWBRT is the wiser choice.
- 1 November 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 84 (4) , 973-982
Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis
- 1 November 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 84 (4) , 973-982
Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis
- 1 February 2012
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 35 (1) , 32-39
Results of the 2005 to 2008 Association of Residents in Radiation Oncology Surveys of Chief Residents in the United States
To analyze the didactics and research experience reported by chief residents during their residency training. During the academic years 2005 to 2006, 2006 to 2007, and 2007 to 2008, the Association of Residents in Radiation Oncology (ARRO) conducted a nationwide survey of all radiation oncology chief residents in the United States. Chi-square statistic was used to assess for changes in didactics and research experience over time. During the years surveyed, an increasing percentage of programs offered curriculum-based didactics in clinical oncology (P=0.042), with a similar trend of borderline significance observed in biostatistics (P = 0.056). Each year, the majority of programs offered >40 hours of curriculum-based training in clinical oncology and physics, >20 hours in radiobiology, and 10 hours or fewer in biostatistics. 11% to 13% of residents reported having no full-time equivalent radiation biologists affiliated with their training program. Less than 64% of programs incorporated mock oral boards into their training. An increasing percentage of programs evaluated residents in a "360 degree" manner, with a trend to significance (P=0.073). Over 80% of programs required resident participation in research activities and allocated dedicated elective research time, typically 4 months or longer. Though the vast majority of programs make clinical research activities available to interested residents, borderline significance (P = 0.051) was observed for a decreasing percentage of such programs during the years analyzed. Trends in didactics and research experience over three years are documented to allow residents and program directors to assess their residency training.
- 1 February 2012
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 35 (1) , 32-39
Results of the 2005 to 2008 Association of Residents in Radiation Oncology Surveys of Chief Residents in the United States
To analyze the didactics and research experience reported by chief residents during their residency training. During the academic years 2005 to 2006, 2006 to 2007, and 2007 to 2008, the Association of Residents in Radiation Oncology (ARRO) conducted a nationwide survey of all radiation oncology chief residents in the United States. Chi-square statistic was used to assess for changes in didactics and research experience over time. During the years surveyed, an increasing percentage of programs offered curriculum-based didactics in clinical oncology (P=0.042), with a similar trend of borderline significance observed in biostatistics (P = 0.056). Each year, the majority of programs offered >40 hours of curriculum-based training in clinical oncology and physics, >20 hours in radiobiology, and 10 hours or fewer in biostatistics. 11% to 13% of residents reported having no full-time equivalent radiation biologists affiliated with their training program. Less than 64% of programs incorporated mock oral boards into their training. An increasing percentage of programs evaluated residents in a "360 degree" manner, with a trend to significance (P=0.073). Over 80% of programs required resident participation in research activities and allocated dedicated elective research time, typically 4 months or longer. Though the vast majority of programs make clinical research activities available to interested residents, borderline significance (P = 0.051) was observed for a decreasing percentage of such programs during the years analyzed. Trends in didactics and research experience over three years are documented to allow residents and program directors to assess their residency training.
- 1 November 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (4) , 1120-1127
Results of the 2005-2008 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States: Clinical Training and Resident Working Conditions
- 1 November 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (4) , 1120-1127
Results of the 2005-2008 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States: Clinical Training and Resident Working Conditions
- 1 December 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (6) , 556-562
Novel insights into the management of brain metastases
This review provides available clinical evidence regarding current therapies, discusses ongoing controversies, and introduces investigational approaches in the management of brain metastases. Novel approaches to estimating prognosis of patients with brain metastases highlight the importance of tailoring treatment to each particular patient. In the setting of unfavorable prognosis, either hospice care, symptom management, or short-course whole-brain radiotherapy (WBRT) is a critical component of palliation. In the setting of favorable or intermediate prognosis, treatment options can include a slightly more prolonged course of WBRT, surgery, stereotactic radiosurgery, systemic therapy, or a combination. Selection of the appropriate treatment is influenced by the number of brain metastases, overall patient performance status and residual life expectancy, as well as an understanding of the benefits and toxicities of each modality. Recent clinical studies have shed novel insight on the temporal sequence of memory changes following WBRT. Innovative approaches to mitigating these radiation-induced memory effects are currently being investigated. Evidence-based management of brain metastases represents an evolving field of active clinical research. Ongoing and future investigations focus on the preservation of cognition and quality of life, in addition to conventional outcomes such as intracranial tumor control and survival.
- 1 December 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (6) , 556-562
Novel insights into the management of brain metastases
This review provides available clinical evidence regarding current therapies, discusses ongoing controversies, and introduces investigational approaches in the management of brain metastases. Novel approaches to estimating prognosis of patients with brain metastases highlight the importance of tailoring treatment to each particular patient. In the setting of unfavorable prognosis, either hospice care, symptom management, or short-course whole-brain radiotherapy (WBRT) is a critical component of palliation. In the setting of favorable or intermediate prognosis, treatment options can include a slightly more prolonged course of WBRT, surgery, stereotactic radiosurgery, systemic therapy, or a combination. Selection of the appropriate treatment is influenced by the number of brain metastases, overall patient performance status and residual life expectancy, as well as an understanding of the benefits and toxicities of each modality. Recent clinical studies have shed novel insight on the temporal sequence of memory changes following WBRT. Innovative approaches to mitigating these radiation-induced memory effects are currently being investigated. Evidence-based management of brain metastases represents an evolving field of active clinical research. Ongoing and future investigations focus on the preservation of cognition and quality of life, in addition to conventional outcomes such as intracranial tumor control and survival.
- 1 December 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 97 (3) , 370-376
Why avoid the hippocampus? A comprehensive review
- 1 December 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 97 (3) , 370-376
Why avoid the hippocampus? A comprehensive review
- 1 September 2010
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 99 (3) , 349-356
Fractionated radiotherapy for intracranial meningiomas
Fractionated external beam radiotherapy (EBRT) has multiple roles in the management of intracranial meningiomas. In multiple series post-operative EBRT has shown improved progression-free survival following subtotal resection and a reduction in long-term failures following an apparent gross total resection. In the definitive setting, the use of EBRT has increased as the growing utilization of neuro-imaging for various conditions identifies skull-based lesions which are not easily resectable. Optic nerve sheath meningiomas represent a classic example of the use of definitive EBRT, given the frequent visual sequelae of surgery or observation. EBRT planning is highly individualized and requires a detailed understanding of tumor grade, adjacent radiosensitive structures such as the anterior optic apparatus, and radiographic characteristics of the tumor such as hyperostosis.
- 1 September 2010
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 99 (3) , 349-356
Fractionated radiotherapy for intracranial meningiomas
Fractionated external beam radiotherapy (EBRT) has multiple roles in the management of intracranial meningiomas. In multiple series post-operative EBRT has shown improved progression-free survival following subtotal resection and a reduction in long-term failures following an apparent gross total resection. In the definitive setting, the use of EBRT has increased as the growing utilization of neuro-imaging for various conditions identifies skull-based lesions which are not easily resectable. Optic nerve sheath meningiomas represent a classic example of the use of definitive EBRT, given the frequent visual sequelae of surgery or observation. EBRT planning is highly individualized and requires a detailed understanding of tumor grade, adjacent radiosensitive structures such as the anterior optic apparatus, and radiographic characteristics of the tumor such as hyperostosis.
- 1 June 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 95 (3) , 327-331
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933
- 1 June 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 95 (3) , 327-331
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933
- 1 November 2006
- Published by Taylor & Francis in Oncology Issues
- Vol. 21 (6) , 24-29
Implementing Hybrid CT/PET
- 1 November 2006
- Published by Taylor & Francis in Oncology Issues
- Vol. 21 (6) , 24-29
Implementing Hybrid CT/PET